Past
Twenty years’ experience in practicing sentinel lymph node biopsy (SLNB) in breast cancer patients demonstrates that residual axillary tumor burden is not synonymous with disease recurrence over time. While meta-analyses have reported a false-negative rate (FNR) for SLNB between 5 and 7%, the reported regional recurrence (RR) rate in node-negative patients is much lower (0.3–0.6%).1 Moreover, landmark randomized controlled trials (RCTs) in patients who do have a tumor-positive SLNB but do not undergo completion axillary lymph node dissection (ALND) show that these patients will also rarely develop axillary recurrences despite an almost 30% chance of having residual positive lymph nodes.2 Apart from an National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-04-like self-limiting phenomenon that we recently demonstrated in a study in SLNB N0 patients who had undergone ablative surgery without receiving further additional treatment and had a RR risk of only 2%,3 adjuvant radiotherapy (RT) and systemic treatments are factors that temper the growth of metastases in the axilla. In the present study, we aimed to quantify the effects of whole-breast RT and systemic treatments on the RR incidence in a large-population-based cohort of SLN N0 breast cancer patients.4
Present
In our study comprising 13,512 patients staged as N0 according to SLNB, the cumulative 5-year RR was 1.4%.4 We demonstrated that RT, as a routine part of breast-conserving therapy (BCT), chemotherapy, and hormonal therapy independently exerted a mitigating effect on the risk of developing RR with hazard ratios of 0.46, 0.31, and 0.40, respectively. None of these treatments had been given with the intent to reduce risk of developing RR. This is the first study to report the magnitude of these effects in a large population-based cohort and may help to explain the observed discrepancy between the FNR of SLNB and RR in N0 patients. Extrapolating the effect size to the SLNB N+ patient category receiving whole-breast RT as routine part of BCT and commonly receiving adjuvant systemic treatment also helps to explain the gap between the rate of additional non-SLNs (27%) and the observed RR of 1.5% without axillary surgery.
Anzeige
Future
The present data may help to explain the discrepancy between residual tumor-positive nodes and the observed RR risk. These data may also be of help to omit axillary surgery in patient categories for whom evidence is scarce. A trial including SLNB-positive patients who had undergone ablative surgery and were randomized to undergo or not axillary clearance was stopped due to slow patient accrual.5 The present data may help to address RR risk in those patients. Given a reported risk of metastatic lymph node involvement and the deployment of these nonsurgical treatment modalities, the subsequent risk of axillary recurrence can be estimated. Another RCT currently investigates whether omitting SLNB in clinically node-negative breast cancer patients undergoing BCT is noninferior to the current axillary staging regimes.6 Based on the reported risk of tumor-positive lymph nodes of 12–16% in this ultrasound-negative patient category, the subsequent risk of RR can be estimated in relation to the nonsurgical treatments.
Disclosures
The authors report no conflicts of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.